Vigil Neuroscience (VIGL) on Monday filed a registration statement for the resale of up to around 5.4 million shares, issuable upon conversion of about 538,000 shares of series A non-voting convertible preferred stock, from time to time by Aventis.
The company said it will not receive any proceeds from the sale of the shares as it is not selling the securities.
The selling stockholder bought the shares in a private placement on July 1, 2024, according to the filing.
Price: 1.80, Change: -0.11, Percent Change: -5.76
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.